Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -132K | 0 | 0 | 0 | 0 |
| Operating Income | -49M | -52M | -34M | -30M | -32M |
| EBITDA | -49M | -48M | -29M | -28M | -33M |
| Net Income | -43M | -48M | -29M | -29M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$17.21
+5.13% today
1Y Change
+147.13%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Trevi Therapeutics, Inc. (TRVI) is a Healthcare stock with a market cap of $1.97B and listed on NASDAQ. The stock last traded around $17.21 and up 147.1% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +38.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +38.3%, free cash flow -10.0% with operating margin 0.0% and ROIC -26.8%. Stock Foundry combines TRVI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TRVI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TRVI Max Drawdown
-29.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TRVI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$33.9M
-16.4% YoY
Free Cash Flow
-$28.9M
-2.2% YoY
Revenue Growth
+0.0%
EPS Growth
+38.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -132K | 0 | 0 | 0 | 0 |
| Operating Income | -49M | -52M | -34M | -30M | -32M |
| EBITDA | -49M | -48M | -29M | -28M | -33M |
| Net Income | -43M | -48M | -29M | -29M | -34M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19M | 34M | 32M | 13M | 37M |
| Total Assets | 193M | 111M | 89M | 123M | 38M |
| Total Liabilities | 10M | 11M | 7M | 16M | 21M |
| Shareholder Equity | 183M | 100M | 83M | 107M | 17M |
| Total Debt | 753K | 1M | 1M | 9M | 15M |
| Net Debt | -18M | -33M | -31M | -3M | -22M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
-2.7% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
29M
-2.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-25.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.